Point-of-Care Diagnostics Market

SKU: DMCD1063 | Last Updated On: Nov 17 2022 | Available Formats

> Point-of-Care Diagnostics Market Expected to reach a high CAGR of 5% By 2029

Point-of-Care Diagnostics Market is segmented By product type (Glucose Monitoring Products (Strips, Meters, Lancets & Lancing Devices), Cardiometabolic Testing Products (Cardiac Marker Testing Products, Blood Gas/Electrolytes Testing Products, HBA1C Testing Products), Infectious Disease Testing Products (Influenza Testing Products, HIV Testing Products, Hepatitis C Testing Products), Coagulation Testing Products (PT/INR Testing Products, Activated Clotting Time (ACT/APTT) Testing Products), Pregnancy and fertility testing products (Pregnancy testing products, Fertility testing products), Tumor/cancer marker testing products, Urinalysis testing products, Cholesterol testing products, Hematology testing products, Drugs-of-abuse testing products, Fecal occult testing products), By Platform (Lateral Flow Assays (Immunochromatography Tests), Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays), By End Users (Hospitals, Ambulatory surgical centers, Diagnostic Centers, Clinical Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Point-of-Care Diagnostics Market Size Share and Growth Rate Analysis

Point-of-Care Diagnostics Market size was valued around US$ YY million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5 % during the forecast period (2022-2029). Point-of-care (POC) diagnostics are procedures carried out near to the patient. POC diagnostic tests provide speedy findings, which improves patient care. Applications of point-of-care diagnostics include diagnosing and detecting glucose levels, infectious diseases, cardiac tests, and among others. These devices are utilized in hospitals, clinics, and patient's homes to respond quickly to various medical tests.

Point-of-Care diagnostics market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Point-of-Care diagnostics market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. The Point-of-Care diagnostics market in the United States and Canada produces the utmost share. Whereas the European Point-of-Care diagnostics market is projected to continue its presence globally during the period of 2022- 2029.

Point-of-Care Diagnostics Market

Metrics

Details

Market CAGR

 5%

Segments Covered

By Product Type, By Platform, By Mode of Purchase, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Point-of-Care Diagnostics Market Growth Drivers and Dynamics

The boom in adoption of latest technology and growing cognizance are expected to drive market growth.

Rising technological advancements is one of the critical component enhancing the marketplace rise, additionally growing POC exams with multiplexing abilities, increasing focus through conferences and events, healthcare decentralisation, and rising markets will create new possibilities for the point-of-care diagnostics for the course during the forecasting period.

Recall of Point of Care diagnostic devices is expected to hamper the market growth.

In October 2021, The US Food and Drug Administration (FDA) warned that certain batches of the Ellume COVID-19 Home Test provided false positive findings due to a manufacturing fault. The company voluntarily recalled specified quantities of its Covid-19 antigen test, which received Emergency Use Authorization (EUA) in December 2020. Nearly 200,000 test kits Ellume has been subject to recall make up approximately 5.6% of the 3.5 million test kits Ellume has shipped to the US, with about 427,000 test kits affected by the problem overall. Thus, from the above factors, the market is expected to be hampered in the forecast period.

Industry Analysis

The point-of-care diagnostics market provides in-depth analysis of the market based on various industry factors such as porter five forces, regulatory approvals, supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. One of the most effective public health measures to stop the spread of SARS-CoV-2 and to effectively manage COVID-19 infections is early detection and isolation of affected people. The diagnosis of SARS-CoV-2 infection is based on clinical symptoms and verified by employing reverse transcription polymerase chain reaction to find the viral RNA in respiratory samples (RT-PCR). Standard RT-PCR procedures are time-consuming, expensive, and technically challenging, making them a poor choice for point-of-care and mass screening in situations with limited resources. It is affordable to scale COVID-19 testing kits at the point-of-care (POC), antigen, and serological tests that have recently been developed, as well as for surveillance operations. Moreover, the global diagnostics alliance Foundation for Innovative New Diagnostics (FIND) announced in April 2021 that it would invest USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to speed up the development, production, and introduction of cost-effective point-of-care molecular diagnostic platforms that can identify multiple disease-causing pathogens, including COVID-19. Thus, from the above factors, the market is expected to boost in the forecast period.

Point-of-Care Diagnostics Market Segment Analysis

Lateral Flow Assays segment is expected to hold the largest market share in point-of-care diagnostics market

The lateral flow assays segment is accounted for the largest market share in 2021. The segment benefits because these are widely used due to their low cost, ease of use, and speed. Lateral flow tests are also simple without special equipment, skills, or experience. Traditional lateral flow tests produce qualitative or semi-quantitative results, whereas quantitative detection requires specialist equipment. For instance, Cytodiagnostics, a biotechnology company based in Burlington, Ontario, Canada, provides the Human IgG Fc Lateral Flow Assay Kit, a 20-minute assay to detect Human IgG Fc in cell culture media and purified protein samples. Its common applications include monitoring expression levels of recombinant antibodies and tracking human Fc-tagged proteins during purification.

Moreover, companies are increasingly focusing on developing innovative lateral flow assay-based point-of-care (POC) devices. For instance, Abbott Laboratories (US) introduced the ARCHITECT STAT Troponin I Blood Test in 2019, while Siemens AG introduced the CLINITEK Microalbumin 2 strips for clinical diagnostics. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Point-of-Care Diagnostics Market Geographical Analysis

North America region holds the largest market share in the global point-of-care diagnostics market

North America accounted for the largest market share in 2021. The increasing prevalence of diabetes, technological advancement in the point of care devices, the rising presence of corroborating government bodies that elevate point-of-care diagnostics or testing in the region and the launch of the product by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the International Diabetes Federation (IDF), the North America and Caribbean region will have 48 million adults with diabetes in 2021, ranging in age from 20 to 79. This amounts to roughly 13% of the local population in this age bracket. Besides, diabetes contributed to at least USD 966 billion in medical costs, or 9% of all adult spending. Therefore, it has increased the demand for glucose monitoring products. PoC testing is widely used to measure glucose levels in hospitalized patients and quickly decide on a course of therapy in response to changes in blood sugar. POC glucose testing is to be accurate, various parameters must be considered before, during, and after the tests.

Moreover, Bond Digital Health, a MedTech company, started a crowdfunding campaign on May 18, 2022, to finish an EU 1.5 million investment round. The business is convinced that digitized PoC diagnostics have the potential to revolutionize healthcare and increase accessibility on a global scale. Thus, from the above factors, the North America region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the point-of-care diagnostics market are F. Hoffmann La-Roche Ltd., Abbott, Siemens Healthcare GmbH, Quidel Corporation, Cepheid, BD, Thermo Fisher Scientific, Biomerieux, Chembio Diagnostics, Inc., EKF diagnostics.

F. Hoffmann La-Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is one of the key market leaders in research-focused healthcare with combined portfolio in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in immunology, infectious diseases, oncology, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, is one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

­Product Portfolio:

cobas h 232 POC system: cobas h 232 POC system is a portable POC  system that supports the optimized treatment of patients with symptoms of chest pain and dyspnea because it provides on-the-spot diagnosis and assessment of the patient’s condition based on objective results.

The global point-of-care diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Trending Topics

Artificial Insemination Methodology Market

Injection Devices for Biological Drugs Market

Bone Grafts And Substitutes Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest